OpenBilldrug price receipt

NADAC week of 2026-10-14

ABILIFY MAINTENA ER 400 MG SYR

FDA nonproprietary name: aripiprazole

For 1 unit (EA)

Pharmacies pay

$2,853.25 filed

1 × $2,853.24574 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part B pays

$2,982.40 derived

1 × $2,982.40 per EA, Part B limit

Medicare's price is not your price.

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)


The spread

1.0× derived

Medicare pays about what pharmacies pay.

Derived because only one labeler, Otsuka America Pharmaceuticals Inc., is listed for HCPCS J0401 on the CMS crosswalk, so the payment limit comes from that company’s own products under the code, not an average across companies.

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Cost-plus estimate

$3,286.24 estimated

$2,853.25 + $427.99 (15%) + $5.00 fee per fill = $3,286.24

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

ABILIFY MAINTENA ER 400 MG SYR is how the CMS NADAC file names this product. The FDA NDC Directory lists it as aripiprazole, under the trade name “ABILIFY MAINTENA”.

FDA gives its dosage form as kit.

The labeler, the company named on the label, is Otsuka America Pharmaceutical, Inc.

FDA lists no Established Pharmacologic Class for it.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 59148-0072-80.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $2,853.25 for 1 unit (EA) (1 × $2,853.24574 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

The NDC

Other strengths, forms and brands

20 other products in the NADAC file share the FDA nonproprietary name aripiprazole with ABILIFY MAINTENA ER 400 MG SYR.

ProductPharmacies pay per unitMedicare per unit
ABILIFY 2 MG TABLET
brand · tablet
$18.65546 per EA filed
eff. 2026-09-23
$22.52657 per EA filed
Part D 2024 average
ABILIFY 5 MG TABLET
brand · tablet
$18.6836 per EA filed
eff. 2026-09-23
$22.52657 per EA filed
Part D 2024 average
ABILIFY 10 MG TABLET
brand · tablet
$18.61552 per EA filed
eff. 2026-09-23
$22.52657 per EA filed
Part D 2024 average
ABILIFY 15 MG TABLET
brand · tablet
$18.65186 per EA filed
eff. 2026-09-23
$22.52657 per EA filed
Part D 2024 average
ABILIFY 20 MG TABLET
brand · tablet
$26.25042 per EA filed
eff. 2026-09-23
$22.52657 per EA filed
Part D 2024 average
ABILIFY 30 MG TABLET
brand · tablet
$26.23171 per EA filed
eff. 2026-09-23
$22.52657 per EA filed
Part D 2024 average
ABILIFY ASIMTUFII 720 MG/2.4 ML
brand · injection, suspension, extended release
$1,785.22689 per ML filed
eff. 2026-09-23
$1,764.23642 per ML filed
Part D 2024 average
ABILIFY ASIMTUFII 960 MG/3.2 ML
brand · injection, suspension, extended release
$1,782.92743 per ML filed
eff. 2026-09-23
$1,764.23642 per ML filed
Part D 2024 average
ABILIFY MAINTENA ER 300 MG SYR
brand · kit
$2,139.08683 per EA filed
eff. 2026-09-23
$2,236.80 per EA derived
Part B limit 2026 Q4
ABILIFY MAINTENA ER 300 MG VL
brand · kit
$2,141.14811 per EA filed
eff. 2026-09-23
$2,236.80 per EA derived
Part B limit 2026 Q4
ABILIFY MAINTENA ER 400 MG SYR this page
brand · kit
$2,853.24574 per EA filed
eff. 2026-09-23
$2,982.40 per EA derived
Part B limit 2026 Q4
ABILIFY MAINTENA ER 400 MG VL
brand · kit
$2,857.76593 per EA filed
eff. 2026-09-23
$2,982.40 per EA derived
Part B limit 2026 Q4
ARIPIPRAZOLE 1 MG/ML SOLUTION
generic · solution
$0.33119 per ML filed
eff. 2026-09-23
We don’t know yet
ARIPIPRAZOLE 2 MG TABLET
generic · tablet
$0.11462 per EA filed
eff. 2026-09-23
$1.54994 per EA filed
Part D 2024 average
ARIPIPRAZOLE 5 MG TABLET
generic · tablet
$0.10973 per EA filed
eff. 2026-09-23
$1.54994 per EA filed
Part D 2024 average
ARIPIPRAZOLE 10 MG TABLET
generic · tablet
$0.11173 per EA filed
eff. 2026-09-23
$1.54994 per EA filed
Part D 2024 average
ARIPIPRAZOLE 15 MG TABLET
generic · tablet
$0.13123 per EA filed
eff. 2026-09-23
$1.54994 per EA filed
Part D 2024 average
ARIPIPRAZOLE 20 MG TABLET
generic · tablet
$0.17429 per EA filed
eff. 2026-09-23
$1.54994 per EA filed
Part D 2024 average
ARIPIPRAZOLE 30 MG TABLET
generic · tablet
$0.17347 per EA filed
eff. 2026-09-23
$1.54994 per EA filed
Part D 2024 average
ARIPIPRAZOLE ODT 10 MG TABLET
generic · tablet / tablet, orally disintegrating
$2.47005 per EA filed
eff. 2026-09-23
$15.55143 per EA filed
Part D 2024 average
ARIPIPRAZOLE ODT 15 MG TABLET
generic · tablet / tablet, orally disintegrating
$2.22394 per EA filed
eff. 2026-09-23
$15.55143 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

What Medicare paid

Medicare Part B’s payment limit for HCPCS J0401, for 2026-10-01 to 2026-12-31, comes to $2,982.40 for 1 unit (EA), or $2,982.40 per EA once converted to NADAC’s unit for this product.

Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $1.4912 per 1 MG.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why does this page start at 1 unit (EA)?
NADAC prices this product per EA, and the FDA NDC Directory lists its NDC as dosage form “KIT” with no route. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and this is not one. NADAC’s EA for it may be the whole kit or one item in it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.